IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas.

ABSTRACT: Pediatric high-grade gliomas (pHGG) and pediatric diffuse midline gliomas (pDMG) are devastating diseases without durable and curative options. Although targeted immunotherapy has shown promise, the field lacks immunocompetent animal models to study these processes in detail. To achieve this, we developed a fully immunocompetent, genetically engineered mouse model (GEMM) for pDMG and pHGG that incorporates the glioma-associated antigen, interleukin 13 receptor alpha 2 (IL13RA2). Utilizing the RCAS-Tva delivery system in Nestin-Tva mice, we induced gliomagenesis by overexpressing PDGFB and deleting p53 (p53^fl/fl) or both p53 and PTEN (p53^fl/fl PTEN^fl/fl), with or without IL13RA2 in neonatal mice. De novo tumors developed in models with and without IL13RA2, s

SUBMITTER: Seblani M 

PROVIDER: S-EPMC11963683 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature